| Date | Title | Description |
| 29.04.2022 | Publication of Annual Report and Financial Statements for the Year ended 31 December 2021 | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Grou... |
| 30.03.2022 | Acacia Pharma to Postpone Publication of its Results for the Full Year 2021, Scheduled on 31 March 2022 | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION
Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or
from any jurisdiction where to do so would constitute a violation of the relevant laws of... |
| 23.03.2022 | Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to Leave the Company | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 23 March 2022: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EUR... |
| 15.03.2022 | Issue of Shares to Employee Benefit Trust | This announcement contains regulated information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 15 March 2022: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the... |
| 21.12.2021 | Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law)
Acacia Pharma Group plc
As previously announced1, Acacia Pharma Group plc issued ordinary shares to i... |
| 16.12.2021 | Correction: Issue of Shares to Employee Benefit Trust | Correction – Admission Date for New Ordinary Shares Included
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 16 December 2021:... |
| 16.12.2021 | Correction: Issue of Shares to Employee Benefit Trust | Correction – Admission Date for New Ordinary Shares Included
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 16 December 2021:... |
| 16.12.2021 | Issue of Shares to Employee Benefit Trust | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the... |
| 13.12.2021 | Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 13 December 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (... |
| 13.12.2021 | Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 13 December 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (... |
| 10.11.2021 | Acacia Pharma to Present at the Jefferies London Healthcare Conference | Cambridge, UK and Indianapolis, US – 10 November 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that its Chief Executive Officer, Mike Bolinder will present at the Jeff... |
| 30.09.2021 | Acacia Pharma : Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption | This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Acacia Pharma Group plc Barhemsys® and Byfavo® launches continue to show strong progress gaining formulary access i... |
| 30.09.2021 | Acacia Pharma : Mid-Year Presentation of Results for the Six Months ended 30 June 2021 | Acacia Pharma Group plc
2021 Mid-Year Results Presentation September 30, 2021
Transforming Medicine Advancing Care
Important Notice
The information contained in this presentation (this "presentation") has been prepared by Acacia P... |
| 23.09.2021 | Correction: Notice of Results | Correction for date of KOL webcast
Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021
Conference Call to be held on 30 September at 14.00 CEST/08.00 EST
Cambridge, UK and Indianapolis, US ... |
| 23.09.2021 | Acacia Pharma : to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 | 23 September 2021 Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021
Conference Call to be held on 30 September at 14.00 CEST/08.00 EST
Cambridge, UK and Indianapolis, US - 23 September 20... |
| 01.07.2021 | Acacia Pharma : Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US | 01 July 2021 Acacia Pharma Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No... |
| 04.05.2021 | ACACIA PHARMA GROUP PLC
Acacia Pharma : Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital | 04 May 2021 Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital
Reduction in Debt Service Obligations
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATI... |
| 30.03.2021 | ACACIA PHARMA GROUP PLC
Acacia Pharma : Publication of Annual Report and Financial Statements for the Year ended 31 December 2020 | 30 March 2021 Publication of Annual Report and Financial Statements for the Year ended 31 December 2020
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, ... |
| 30.03.2021 | ACACIA PHARMA GROUP PLC
Acacia Pharma : Annual Report and Financial Statements for the Year ended 31 December 2020 | Acacia Pharma Group plc Annual Report and Financial Statements
for the year ended 31 December 2020
Registered number 09759376
Directors and advisersAcacia Pharma at a glanceStrategic Report
1 2
Chairman's introduction 3
CEO's review 5
Our b... |
| 30.03.2021 | Acacia Pharma : Annual Report and Financial Statements for the Year ended 31 December 2020 | Acacia Pharma Group plc Annual Report and Financial Statements
for the year ended 31 December 2020
Registered number 09759376
Directors and advisersAcacia Pharma at a glanceStrategic Report
1 2
Chairman's introduction 3
CEO's review 5
Our b... |
| 26.02.2021 | Issue of Equity on Exercise of Options/Vesting of Performance Share Awards | Acacia Pharma Group plc
Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
Cambridge, UK and Indianapolis, US – 26 February 2021, 08:00 CET: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EU... |
| 19.02.2021 | Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 19.02.2021 | Acacia Pharma (EURONEXT: ACPH) raises EUR 27 million for US launch | Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments... |
| 19.02.2021 | ACACIA PHARMA GROUP
Acacia Pharma : Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 19.02.2021 | Acacia Pharma : Results of Placing – EUR 27 million Raised to Invest Further in US Launch and Commercialization Activities | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 18.02.2021 | Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS® | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 18.02.2021 | Change of EU home Member State | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION
Acacia Pharma Group plc
Change of EU home Member State
Cambridge, UK and Indianapolis, US – 18 February 2021, 09:00 CET: Acacia Pharma Group plc ("Acacia Pharma" or the "Compan... |
| 18.02.2021 | Acacia Pharma : Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS® | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 18.02.2021 | ACACIA PHARMA GROUP
Acacia Pharma : Proposed Capital Raising by way of a Placing of New Ordinary Shares and Update on Early Positive Market Reception to US Launch of BARHEMSYS® | THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 12.02.2021 | Issue of Equity on Exercise of Options/Vesting of Performance Share Awards | Acacia Pharma Group plc
Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
Cambridge, UK and Indianapolis, US – 12 February 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACP... |
| 12.10.2020 | COSMO PHARMACEUTICALS N.V.
Cosmo Pharmaceuticals N : Acacia Pharma completes drawdown from EUR25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS and BYFAVO | Cambridge - Acacia Pharma Group plc ('Acacia Pharma', the 'Group' or the 'Company') (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients... |
| 09.10.2020 | ACACIA PHARMA GROUP
Acacia Pharma : completes drawdown from 25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™ | Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regu... |
| 14.08.2020 | Acacia Pharma raises €25M to launch BARHEMSYS® and BYFAVO™ in the US | Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatmen... |
| 27.02.2020 | Acacia Pharma's twice spurned drug finally makes the FDA cut | Third time’s the charm for Acacia Pharma.
The Cambridge, UK-based company on Thursday finally secured FDA approval for its treatment for patients with postoperative nausea & vomiting (PONV), who are symptomatic des... |
| 03.05.2019 | FDA rejects Acacia's lead drug — again — due to the same manufacturing issue | Acacia Pharma did well on the R&D front — by 2017, it had conducted four positive pivotal clinical trials for its lead drug, Barhemsys. Later that year, it submitted an FDA application to market the drug for rescue tr... |
| 02.07.2018 | Acacia Pharma secures $30 million debt finance to support intended commercialisation of BARHEMSYS™ in the US | Cambridge, UK and Indianapolis, US - Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has secured a ... |
| 02.03.2018 | Acacia Pharma Group raises €40m at IPO for US growth | - |
| 04.09.2013 | Acacia Pharma Raises £15M in Series B Financing | Acacia Pharma, a Cambridge, UK-based pharmaceutical company specializing in the development of drugs for supportive care, raised £15m (approximately $23.5m) in Series B financing.
The round was led by Fidelity Biosciences and Novo A/S, with... |
| 03.09.2013 | Acacia Pharma Announces £15M ($23.5M) Series B Financing | Cambridge, UK – Acacia Pharma, the pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million ($23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Cu... |
| 03.09.2013 | Acacia Pharma Raises $23.5M |
CAMBRIDGE, ENGLAND, Pharmaceutical company specializing in the development of drugs for supportive care, announces it has raised POUND 15 million ($23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.
>> ... |
| 31.03.2011 | Acacia Pharma Closes $10 Million Investment Round | Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ven... |
| 31.03.2011 | Acacia Pharma Closes $10M Series A Funding Round | Acacia Pharma, a Cambridge, UK-based pharmaceutical company specializing in the development of drugs for cancer supportive care, has closed a $10m Series A funding round.
New investor Lundbeckfond Ventures joined Gilde Healthcare.
Acacia Ph... |
